Study Protocol:
Increasing Influenza Vaccination in
Individuals
with Cardiovascular Conditions:
Assessing the Effectiveness
of a
Digital Intervention in a Decentralized Randomized Controlled
Trial
Principal Investigator: 
Nell Marshall, DrPH
Sub-Investigators: 
Jennifer Lee, PhD 
Wei-Nchih Lee, MD, PhD, MPH 
Jessica Schroeder, PhD
Sponsor: 
Evidation Health
Research Partner: 
Sanofi Pasteur
Protocol appr oval date (Resear ch Partner -Sanofi Pasteur): 1 1 August 2020
Protocol appr oval date (Evidation Health): 1 1 August 2020
NCT  Number:
[STUDY_ID_REMOVED]
Version 1
1
of
22
Table of Contents
List of Abbr eviations
4
Statement of Compliance
5
Protocol Summary
5
1.  Intr oduction
8
1.1. Overview of Therapy Area
8
1.2. Study Rationale
8
1.3. Intervention Overview
8
2.  Study Objectives
9
2.1. Primary Objective
9
2.2. Secondary Objectives
9
2.3 Exploratory Objectives
9
3.  Study Design
10
3.1. Overall Design
10
4.  Study Endpoints
10
4.1. Primary Endpoint
10
5. Study Population
11
5.1. Inclusion and Exclusion Criteria
11
5.2. Recruitment Methods
11
6.1. Study Enrollment
12
6.2. Informed Consent
12
6.3. Study Steps
12
6.4. Study Compliance
13
6.5. Compensation
13
6.6. Study Flow Diagram
13
8. Statistical Considerations
16
8.1. Sample Size Justification
16
8.2. Description of Analytical Plan
17
8.2.1. Baseline Descriptive Statistics
17
Version 1
2
of
22
8.2.2. Analysis of Primary Endpoint
17
8.2.3. Analysis of Secondary Endpoint
18
8.2.4. Exploratory Analyses
18
9.  Data Security and Confidentiality
19
10.  Risks and Benefits
19
10.1. Potential Risks Associated with the Study
20
10.2. Potential Benefits Associated with the Study
20
10.3. Adverse Events
20
Appendix
21
Refer ences
21
Version 1
3
of
22
List of Abbreviations
IRB
Institutional Review Board
LAR
Legally Authorized Representative
PII
Personally Identifiable Information
TLS
Transport Layer Security
CDC
Centers for Disease Control and Prevention
ePRO
Electronic Patient Reported Outcomes
RCT
Randomized Controlled Trial
CVD-I
Cardiovascular disease-intervention
CVD-C
Cardiovascular disease-control
Version 1
4
of
22
Statement of Compliance
The
protocol,
Data
Usage
Agreement
&
Permissions
form,
recruitment
materials,
and
all 
participant
materials
will
be
submitted
to
the
Solutions
Institutional
Review
Board
for
review 
and
approval.
Approval
of
both
the
protocol
and
the
Data
Usage
Agreement
&
Permissions
form 
must
be
obtained
before
any
participant
is
enrolled.
Any
amendment
to
the
protocol
or
Data 
Usage
Agreement
&
Permissions
form
will
require
review
and
approval
by
Solutions
IRB
before 
the
changes
are
implemented
to
the
study .
A
determination
will
be
made
regarding
whether
a 
new
Data
Usage
Agreement
&
Permissions
form
needs
to
be
obtained
from
participants
who 
provided
agreement
to
participate
using
a
previously
approved
Data
Usage
Agreement
& 
Permissions form.
Protocol Summary
Title
Increasing Influenza Vaccination in Individuals with 
Cardiovascular Conditions:
Assessing the Ef fectiveness
of a 
Digital Intervention in a Decentralized Randomized
Controlled Trial
Study Design
A 6-month prospective, digital randomized controlled trial
targeting approximately 35,000 individuals to evaluate the
effectiveness of an influenza vaccination intervention during
influenza season for people with cardiovascular conditions
Objectives
Primary:
To determine the ef fectiveness of a digital intervention
designed to increase influenza vaccination rates in individuals
with cardiovascular disease (CVD) by examining:
â—
Differences in self-reported influenza vaccination rates
between individuals with cardiovascular disease who
receive a tar geted digital intervention (CVD-I) aimed
at increasing influenza vaccination and those with
cardiovascular disease who received no intervention
(CVD-C) by the end of the study period
Secondary:
1)
To examine dif ferences in vaccination rates between
individuals in the intervention group who engaged
with dif ferent numbers of intervention messages, and
changes in self-reported vaccination rates following
intervention messages
Version 1
5
of
22
2)
To describe levels of engagement with the intervention
messages and perceptions of the intervention messages
within the CVD-I group
3)
To examine predictors of vaccination status, including
cardiovascular condition type, vaccine drivers/barriers,
and vaccine knowledge, across diagnoses and within
CVD-I and CVD-C groups
Exploratory:
1)
To examine the potential impact of COVID-19
pandemic on influenza vaccination rates
2)
To describe self-reported complications from
influenza experienced by individuals with dif ferent
cardiovascular conditions during the 6-month study
period, as well as dif ferences in complications by
vaccination status
3)
To examine dif ferences in wearable data (e.g., sleep,
steps, heart rate) between individuals who experience
self-reported influenza and those who do not, as well
as dif ferences in wearable data between cardiovascular
conditions
Endpoints
Primary endpoint 
â—
Self-reported influenza vaccination rates
Secondary endpoints 
â—
Engagement with interventions (i.e., clicking, opening,
completing) 
â—
Self-reported vaccine drivers/barriers, and vaccine
knowledge 
Exploratory endpoints
â—
Self-reported impact of COVID-19 on influenza
vaccination behavior
â—
Self-reported complications from influenza
â—
Passively collected wearable data (e.g., sleep, steps,
heart rate)
Version 1
6
of
22
Patient Population
Inclusion Criteria:
â—
Age 18 years or older 
â—
Resides in the U.S. 
â—
Speaks, reads, and understands English 
â—
Has self-reported being diagnosed with any of the
following cardiac conditions below in their
Achievement profile:
â—‹
Atrial Fibrillation or Afib 
â—‹
Abnormal or irregular heart rhythm, other
arrhythmic heart disease 
â—‹
Cardiac arrest, or heart attack (myocardial
infarction) 
â—‹
Coronary heart disease like a heart blockage,
treated with medications, a stent in the heart, or
sometimes bypass sur gery 
â—‹
Heart failure, like congestive heart failure 
â—‹
Stroke or cerebrovascular accident (CV A) 
Exclusion Criteria:
â—
Participated in Step 1, Part 2 semi-structured
interviews used to obtain feedback on the intervention
messages
Version 1
7
of
22
1.Introduction
1.1. Overview of Therapy Area
Influenza impacts approximately 5-20% of the population of the United States annually , resulting 
in significant economic impact and public health burden (Molinari et al., 2007). For people with
cardiovascular conditions, influenza can be particularly burdensome, thus they are considered a
high-risk group (CDC, 2019). Vaccination for influenza remains the most ef fective primary 
prevention method against influenza, with ef fectiveness ranging from 38-48% in the past few 
years (Centers for Disease Control and Prevention (CDC), 2018; Dos Santos, Tahrat, & 
Bekkat-Berkani, 2018; Doyle, 2019; Jackson et al., 2017; Rolfes et al., 2019). The CDC reports 
that the vaccination rate in the 2018-2019 season was 47.9%  for individuals 18-64 years of age
who have high risk conditions such as cardiovascular conditions (CDC, 2019). While this is 
higher than the rate of 36.4% in same age individuals without high risk conditions, it is far below
the 70% national vaccination rate goal (Healthy People 2020, 2019). Given the increased burden
that influenza represents for people with high risk conditions, even small improvements in
vaccination rates could result in significant impact and provide benefit to patients, healthcare
providers, and insurance payors (Molinari et al., 2007).
1.2. Study Rationale
To date, there are no lar ge-scale RCT s on digital interventions for increasing vaccination rates in 
people with cardiovascular conditions. One observational study has demonstrated the potential
effectiveness of general messaging and incentives via a health-related app to increase vaccine
uptake in the general Canadian population (Dale, White, Mitchell, & Faulkner , 2019), suggesting 
this kind of intervention could be ef fective with people with cardiovascular conditions. In a 
separate study , a lar ge randomized controlled trial (RCT) using digital messaging with incentives 
to vaccinate was found to be ef fective in increasing vaccination rates in a general population of 
adults in the United States (Lee et al., 2020).  Of particular interest is a digital RCT  in a sample 
of individuals with diabetes, a population with increased risk of influenza-related complications,
that used digital messaging and was found to be ef fective in increasing vaccination rates 
(Samson, et al., 2020). An additional study of individuals with diabetes that was a collaboration 
between Sanofi Pasteur and Evidation also demonstrated the impact of influenza and related
complications on data retrieved from wearables; showing that people who developed influenza
engaged in less activity around the time of diagnosis and recorded an increased heart rate, a
unique passive marker of infection (Samson et al., 2019). These studies all suggest that the 
development of a digital intervention tar geted to individuals with cardiovascular conditions could 
be beneficial in increasing vaccination rates.
1.3. Intervention Overview
Version 1
8
of
22
The digital intervention messages were developed using a 3-part approach: 1) a quantitative
assessment of more than 800 patient perspectives for people with cardiovascular disorders,
assessing their behaviors, thoughts, and beliefs surrounding vaccination; 2) semi-structured
interviews with approximately 25 patients who had cardiovascular diseases to gather their
perspectives and feedback on proposed intervention messages; and 3) an expert panel of
cardiologists, behavioral scientists, and vaccine policy experts for expert input on content and
accuracy of scientific information provided. This approach to intervention development was 
consistent with the Patient Centered Outcomes Research Institute (PCORI) recommendation for
developing interventions that increase participant recruitment and retention, improve patient
outcomes, and increase research validity and relevance to the real world (Frank, Basch, & Selby , 
2014). The intervention messages provide informational content on the influenza vaccine 
(sourced from the Centers for Disease Control and Prevention and the American Heart 
Association), specific information about influenza and cardiovascular disorders, and behavioral
prompts (e.g., reminders) surrounding influenza vaccination behaviors.
2.Study Objectives
2.1. Primary Objective
â—
To determine the ef fectiveness of a digital intervention designed to increase influenza 
vaccination rates in individuals with cardiovascular diagnoses (CV  diagnoses) by 
examining dif ferences in self-reported influenza vaccination rates between individuals 
with cardiovascular disease who receive a tar geted digital intervention (CVD-I) aimed at 
increasing influenza vaccination and those with CV  diagnoses who received no 
intervention (CVD-C) by the end of the study period.
2.2. Secondary Objectives
â—
To examine dif ferences in vaccination rates between individuals in CVD-I who engaged
with dif ferent numbers of intervention messages, and changes in self-reported vaccination
rates following intervention messages
â—
To describe levels of engagement with the intervention messages and perceptions of the
intervention messages within the CVD-I group
â—
To examine predictors of vaccination status, including cardiovascular condition type,
vaccine drivers/barriers, and vaccine knowledge, across diagnoses and within CVD-I and
CVD-C groups
2.3 Exploratory Objectives
â—
To examine the potential impact of COVID-19 pandemic on vaccination rates
Version 1
9
of
22
â—
To describe self-reported complications from influenza experienced by individuals with
different cardiovascular conditions during the 6-month study period, as well as
differences in complications by vaccination status
â—
To examine dif ferences in wearable data (e.g., sleep, steps, heart rate) between
individuals who experience self-reported influenza and those who do not, as well as
differences in wearable data between cardiovascular conditions
3.Study Design
3.1. Overall Design
â—
A 6-month prospective, digital randomized controlled trial tar geting approximately 
35,000 individuals to evaluate the ef fectiveness of an influenza vaccination intervention 
during influenza season for people with cardiovascular conditions 
â—
Two study arms: cardiovascular disorders digital intervention arm (CVD-I) &
cardiovascular disorders without digital intervention arm (control: CVD-C)
4.Study Endpoints
4.1. Primary Endpoint
The primary endpoint in this study is to examine dif ferences in self-reported influenza 
vaccination rates between individuals with cardiovascular disease who receive a tar geted digital 
intervention (CVD-I) aimed at increasing influenza vaccination and those with cardiovascular
disease who received no intervention (CVD-C).
4.2. Secondary Endpoint
The secondary endpoints in this study are: 
â—
To examine predictors of vaccination status, including cardiovascular condition type,
vaccine drivers/barriers, and vaccine knowledge, across and between CVD-I and CVD-C. 
â—
Engagement with interventions, including clicking, opening, or completing the
intervention messages
4.3. Exploratory Endpoints
The exploratory endpoints in this study include: 
â—
To describe the self-reported impact of the COVID-19 pandemic on influenza vaccination
behavior
Version 1
10
of
22
â—
To describe self-reported complications from influenza experienced by individuals with
different cardiovascular conditions during the 6-month study period, as well as
differences in complications by vaccination status. 
â—
To examine dif ferences in wearable data (i.e., sleep, steps, heart rate) between individuals 
who experience influenza and those who do not, as well as dif ferences in wearable data 
between cardiovascular conditions.
5.Study Population
5.1. Inclusion and Exclusion Criteria
Inclusion Criteria
Exclusion Criteria
â—
Age 18 years or older 
â—
Resides in the U.S. 
â—
Speaks, reads, and understands
English 
â—
Has self-reported being diagnosed
with any of the following cardiac
conditions below in their
Achievement profile:
o
Atrial Fibrillation or Afib 
o
Abnormal or irregular heart
rhythm, other arrhythmic
heart disease
o
Cardiac arrest, or heart attack
(myocardial infarction)
o
Coronary heart disease like a
heart blockage, treated with
medications, a stent in the
heart, or sometimes bypass
surgery 
o
Heart failure, like congestive
heart failure
o
Stroke or cerebrovascular
accident (CV A)
â—
Participated in Step 1, Part 2
semi-structured interviews used to
obtain feedback on the intervention
messages.
5.2. Recruitment Methods
Achievement, a product of Evidation Health, is an online platform where people can connect
their digital health tools, including wearable activity trackers and fitness apps. Achievement
Version 1
11
of
22
members agree to being contacted with study opportunities when they create an Achievement 
account. Evidation Health will leverage Achievement for recruitment, and will use an online 
strategy and study platform to develop a tar get list of participants, verify eligibility , and enroll 
participants into this study .
A set of existing Achievement members who have previously self-reported to meeting the 
inclusion criteria will be tagged for study inclusion, termed â€œparticipantsâ€ from here on. Since
participants will be blinded to their study participation status, participants will not be asked to
take any action to enroll in the study . In order to identify a tar get list of participants, Evidation 
Health will leverage already permissioned information from Achievement members, including 
data on their cardiovascular diagnoses, age, sex/gender , race/ethnicity , and country of residence. 
These participants will be randomized using block randomization into CVD-Intervention or
CVD-Control prior to being of fered the opportunity to complete any study activities. 
Randomization will ensure that the groups are representative of the general Achievement 
population with cardiovascular disease. Ef forts will be made to tar get individuals for enrollment 
who identify as being of a race/ethnicity that is something other than non-Hispanic White, as 
well as representative in sex/gender . Participants will be sent of fers via the Achievement 
platform to complete study activities. Participants can complete any number of survey activities
(demographics, baseline, 3-month survey , and/or 6-month survey , intervention messages); 
completion of intervention activities will not be required for enrollment for the CVD-I group.
6.
Study Procedures
6.1. Study Enr ollment
Participants will be sent of fers on the Achievement Studies Platform to complete study activities. 
Participants can complete any number of survey activities (baseline, 3-month survey , and/or 
6-month survey , intervention messages); completion of intervention activities will not be 
required for enrollment for the CVD-I group.
6.2. Informed Consent
We will request that informed consent is exempt for this study for the following reasons: 
â—
Participation in this study involves no more than minimal risk to the privacy of
individuals. 
â—
Given the nature of the study , which aims to measure influenza vaccination rates in a 
real-world setting, priming the participants with a consent form will likely alter the
perception of the interventions and may impact how individuals respond to the study
assessments, potentially biasing the results and limiting the generalizability of the
findings. For this reason, this study could not be practically carried out without the
waiver of informed consent. 
â—
At the beginning of each questionnaire, participants will be notified on how their survey
responses and behavioral data will be used for research purposes via a Data Usage &
Permissions Agreement.
Version 1
12
of
22
6.3. Study Steps
Participants will be sent an of fer to complete a survey at baseline, 3 months, and 6 months. A 
separate demographic and medical history survey will remain available for participants to
complete throughout the study . Additional information on study experiences and intervention 
feedback will be gathered in the 6-month survey for those in the CVD-I group. Data from an
activity tracker will be collected if one is already connected to the participantâ€™ s Achievement 
account, consistent with their completion of the Data Usage & Permissions Agreement. Activity 
tracker data will be collected retrospectively and prospectively . Participants in the CVD-I arm 
only will be sent intervention messages on predetermined days for the duration of the 6-month
study intervention period. At the end of the intervention period, individuals who completed a 
data usage and permissions agreement as a part of the surveys will be informed via email that the
survey information they contributed was for a research study investigating influenza vaccination
behavior in people with cardiovascular conditions.
6.4. Study Compliance
Evidation study staf f will track whether participants are completing study-related tasks 
throughout the study . Participants who do not complete study activities may be contacted by 
email, text message, or push notifications with reminders to complete activities, within a time
window that is appropriate to the specific task, but will remain in the study sample regardless of
whether they submit data in a timely manner .
6.5. Compensation
Participants in both arms will be compensated for completing surveys. Participants in the CVD-I
will be compensated minimally for the completion of intervention tasks (e.g., completing short
quizzes, scheduling a date for their influenza vaccine, reading an article to learn more about the
flu, the flu shot, and their cardiovascular conditions), to avoid incentivizing vaccination status
unequally between the two arms. The compensation amounts will be detailed in the Data Usage 
& Permissions Agreements at the beginning of each survey for CVD-I and CVD-C arms, and in 
the of fer to complete the intervention messages for the CVD-I arm. All compensation will be 
awarded in Achievement Points, of which 100 points is equivalent to $0.10. Points can be 
redeemed for monetary compensation or donated to charitable or ganizations. The following 
compensation will be awarded: 50 points per intervention message completed, 3 points per
optional informational email requested, and 300 points per survey completed. The maximum 
number of points possible is 1,518 points, which could be redeemed for approximately $1.52.
6.6. Study Flow Diagram
Version 1
13
of
22
Note.
Dates are approximate.
7.
Data Types and Outcomes
â—
Data from self-reported survey:
â—‹
Demographics
â—‹
Medical history
â—‹
Health behaviors
â—‹
Healthcare utilization
â—‹
Influenza vaccination status, experience, and complications
â—‹
COVID-19 experiences
â—‹
Vaccine attitudes and barriers 
â—‹
Influenza risks and healthcare provider role
â—‹
Experience and perceptions of intervention materials  (CVD-I only)
â—
Data from engagement with interventions (CVD-I only)
â—‹
For example, clicks, dismissals, or completions of interventions
â—
Data from Achievement Profile
â—‹
Activity data generated by wearables (e.g., heart rate, sleep, step data), from 12
months before participation and 12 months after participation (if available)
Source
Retrospective
Demographics
Baseline
Month 3
Month 6
Version 1
14
of
22

12 months before to
12 months after
Survey
Self-reported data
Demographics
Survey
X
Medical history
Survey
X
Health behavior
history & influenza
vaccination
Survey
X
Healthcare
utilization
Survey
X
X
X
Influenza
vaccination status
Survey
X
X
X
Influenza experience
& complications
Survey
X
X
X
COVID-19
experiences &
perceptions
Survey
X
X
X
Vaccine drivers &
barriers
Survey
X
X
X
Influenza risks &
healthcare provider
role
Survey
X
X
X
Experience and
perceptions of
intervention
materials
Survey
X
(CVD-I
only)
Engagement with
interventions
Achievement
website/app
and Survey
Monkey
[------------continuous---------------] 
(CVD-I only)
Activity tracker data
Steps
[e.g. Fitbit,
Garmin]
X 
[------------continuous---------------]
Sleep 
[e.g. Fitbit,
Beddit]
X 
[-------------continuous--------------]
Heart rate
[e.g. Fitbit,
Apple]
X 
[--------------continuous-------------]
8.Statistical Considerations
Version 1
15
of
22
8.1. Sample Size Justification
We determined sample size for a two-arm interventional statistical superiority study design with
vaccination rates as the primary outcome of interest (Zhong 2009). Studies on the impact of
messaging and reminders to improve influenza vaccination rates show a range of ef fect sizes 
from 2.5 - 3.5% (Nehme et al., 2019, Hurley et al., 2018). As noted earlier , CDC reported 
vaccination rates are 47.9% for adults between the ages of 18 - 65.
Given these a-priori assumptions, we assumed dif ferent baseline vaccination rates of 35%, 50% 
and 60%, and then computed the sample size needed to detect an increase in vaccination rate of
2%, 3% and 4% respectively . Sample size for the dif ference in proportion is determined by 
(Zhong, 2009):
Where:
Z
Î±/2
and Z
Î²
refer to the z critical values for a type
I and II error of 0.05 and 0.2 respectively , 
p
0
and p are the baseline proportion and the new hypothesized
proportion respectively , and 
N is the total sample size, assuming a 1:1 ratio of intervention to control
Baseline
vaccination
rate
Hypothesized
vaccination
rate
Hypothesized
effect size
Hypothesized
Cohen's h
Sample size
35.0%
37.0%
2.0%
4.2%
18080
50.0%
52.0%
2.0%
4.0%
19610
60.0%
62.0%
2.0%
4.1%
18668
35.0%
38.0%
3.0%
6.2%
8080
50.0%
53.0%
3.0%
6.0%
8710
60.0%
63.0%
3.0%
6.2%
8256
35.0%
39.0%
4.0%
8.3%
4570
50.0%
54.0%
4.0%
8.0%
4894
60.0%
64.0%
4.0%
8.2%
4618
In the above table, for each baseline rate and hypothesized rate increase (and associated Cohenâ€™ s 
h), we show the estimated total sample size needed for each assumption of baseline vaccination
Version 1
16
of
22

rate and ef fect size. We note that within each hypothesized ef fect size, changing assumptions 
about baseline vaccination rates do not substantially alter the sample size.
Based on this, we believe that a 3% ef fect size is a reasonable assumption and that a sample size 
of approximately 8000 participants will be needed to detect this dif ference with a type I error rate 
of 0.05 and a presumed power of 0.80. A participation dropof f of 67% has been observed for 
digital interventions for increasing influenza vaccination (i.e., Samson et al., 2020). Assuming 
between 67% to 75% dropof f for this study , we estimate that between 24,000 - 35,000 
participants will need to be recruited and randomized for this study . Based on these calculations, 
we plan to recruit approximately 35,000 participants.
8.2. Description of Analytical Plan
8.2.1. Baseline Descriptive Statistics
Descriptive statistics (e.g., mean, standard deviation, frequency and percentage) of study
participants will be reported for demographic variables (e.g., age, gender , education, income) and 
patient reported outcomes (e.g., vaccination rates). To confirm that block randomization is 
successful, we will compare the intervention to control groups in terms of baseline
demographics, vaccine drivers/barriers, and vaccine knowledge for each of the block groups
described earlier .
8.2.2. Analysis of Primary Endpoint
An intention to treat analysis will be conducted of the primary outcomes for the study . Assuming 
that a descriptive comparison of the intervention to control group does not demonstrate
statistically significant dif ferences in terms of demographics, vaccine drivers/barriers, or vaccine 
knowledge, we will report on the relative rate of influenza vaccination for the intervention group
compared to the control group. We will also conduct logistic regression modeling of influenza 
vaccination as follows:
ğ‘™ğ‘œğ‘”ğ‘–ğ‘¡(ğ‘Œ) =Î²0 +Î²1 ğ‘€ + âˆ‘ğ‘—Î²ğ‘—Î±ğ‘— + Îµ
Where:
logit(Y)
=
ln(Y/1-Y)
for the binary variable designation
of influenza vaccination status 
M
= the binary designation for Intervention (messaging)
vs Control (no messaging) 
Î±
j
= the baseline covariates measured in the study
(e.g. demographics, vaccine drivers/barriers or 
knowledge)
Îµ = 
the error term of the regression.
For the logistic regression model the p-values associated with each of the 
Î² 
parameter estimates 
will be reported.
Version 1
17
of
22
8.2.3. Analysis of Secondary Endpoint
To examine dif ferences in vaccination rates between individuals in the CVD-I group and its 
relationship to engagement with intervention messages, we will model:
ğ‘™ğ‘œğ‘”ğ‘–ğ‘¡(ğ‘Œ) =Î²0 +Î²1 ğ‘€ + âˆ‘ğ‘—Î²ğ‘—Î±ğ‘—+ Îµ
Where:
logit(Y)
=
ln(Y/1-Y)
for the binary variable designation
of influenza status 
M
= the number of engaged messages (ordinal variable
0, 1, 2, 3, 4, 5, 6) 
Î±
j
= the baseline covariates measured in the study
(e.g. demographics, vaccine drivers/barriers, or 
knowledge)
To examine predictors of vaccination status, including cardiovascular condition type, vaccine
drivers/barriers, and vaccine knowledge, across CVD-I and CVD-C we will construct the model:
ğ‘™ğ‘œğ‘”ğ‘–ğ‘¡(ğ‘Œ) =Î²0 +Î²1 ğ‘ƒ + âˆ‘ğ‘—Î²ğ‘—Î±ğ‘— + Îµ
Where:
logit(Y)
=
ln(Y/1-Y)
for the binary variable designation
of influenza status 
C
i
= the binary designation Cardiovascular Condition
as described earlier 
P
= the predictor of interest (e.g. cardiovascular
condition, vaccine drivers/barriers, vaccine 
knowledge index)
Î±
j
= the baseline covariates measured in the study
(e.g. demographics, vaccine drivers/barriers, or 
knowledge)
Îµ = 
the error term of the regression.
To examine predictors of vaccination status, including cardiovascular condition type, vaccine
drivers/barriers, and vaccine knowledge, within CVD-I or CVD-C we will construct the model:
ğ‘™ğ‘œğ‘”ğ‘–ğ‘¡(ğ‘Œ) =Î²0 +Î²1 ğ‘€ +Î²2 ğ‘ƒ + âˆ‘ğ‘—Î²ğ‘—Î±ğ‘— + Îµ
Where:
logit(Y)
=
ln(Y/1-Y)
for the binary variable designation
of influenza status 
M
= the messaging group being examined (either Intervention
or Control) 
P
= the predictor of interest (e.g. cardiovascular
condition, vaccine drivers/barriers, vaccine 
knowledge index)
Î±
j
= the baseline covariates measured in the study
(e.g. demographics, vaccine drivers/barriers, or 
knowledge)
Îµ = 
the error term of the regression.
8.2.4. Exploratory Analyses
To examine the potential impact of COVID-19 on vaccination rates, we will add  a term to the
model used in the primary analysis model:
Version 1
18
of
22
ğ‘™ğ‘œğ‘”ğ‘–ğ‘¡(ğ‘Œ) =Î²0 +Î²1 ğ‘€ + âˆ‘ğ‘—Î²ğ‘—Î±ğ‘— +Î²ğ‘ğ‘ +Î²ğ‘–ğ‘€*ğ‘+ Îµ
Where the additional term
c
is the Covid-19 status
(1 if diagnosed with COVID-19, 0 if not) and 
the parameter estimate for the interaction term,
will be reported. Similarly , we can alsoÎ²ğ‘– 
evaluate the ef fect of COVID-19 attitudes towards influenza vaccination rates. In this case, the 
term
c
would represent COVID-19 attitudes (1 if the
participant reports more likely to vaccinate, 
0 if the person does not).
To describe self-reported complications from influenza experienced by individuals with dif ferent 
cardiovascular conditions during the 6-month study period, as well as dif ferences in 
complications by vaccination status, we will aggregate rates of self-reported complications by
cardiovascular conditions, as well as by vaccination status.
To examine dif ferences in wearable data (i.e., sleep, steps, heart rate) between individuals who 
experience influenza and those who do not, as well as dif ferences in wearable data between 
cardiovascular conditions, we will aggregate day-level wearable data over the entire study period
based on influenza status, as well as by cardiovascular condition.
Between-group comparisons of the outcomes described above (e.g. self reported complications
or mean daily steps) will be conducted with Studentâ€™ s t-tests or the non-parametric 
Mann-Whitney U test when appropriate, with correction for multiple testing using the
Benjamini-Hochber g approach for False Discovery Rate correction.
9.Data Security and Conï¬dentiality
All identifiable information about participants, their medical conditions, and other study data will
be secured by Evidation Health in accordance with all applicable local and state laws,
regulations, and IRB policies regarding collection and distribution of participant information.
Data will be transmitted using secure encrypted protocols and stored on encrypted disks on
secure and hardened servers. Administrative access to these servers is limited to only the 
necessary IT  staff at Evidation Health. Survey data may be stored for a minimum of 3 years, 
consistent with contract and applicable law .
Personally Identifiable Information (PII) is only accessible to a restricted set of individuals, and
is only used to distribute study material and for participant support purposes. PII will not be
disclosed unless required by regulatory agencies or the IRB in instances consistent with
applicable law . Limited Achievement clinical, research and technical team members at Evidation 
Health only have access to Coded Study Data where all PII is replaced with random unique
identifiers. Coded Study Data may also be transferred to external research partners, including
Sanofi Pasteur , in accordance with IRB approved uses.
10.Risks and Beneï¬ts
Version 1
19
of
22
10.1. Potential Risks Associated with the Study
This is a minimal risk study that does not involve any risk beyond what a person would
experience in their daily life. While we strive to protect the privacy of personal information and 
implement appropriate safeguards, complete security cannot be guaranteed. There is the potential 
risk of loss of privacy associated with this study if another person sees the participantâ€™ s survey 
responses on their phone or computer screen. Participants may decline to answer certain survey
questions.
10.2. Potential Benefits Associated with the Study
Participants of this study will likely not receive any direct benefit from the proposed research;
however , society and investigators will benefit from the knowledge gained. This information 
may contribute to public health and scientific ef forts related to vaccination and the prevention of 
disease for people with cardiovascular disorders. This information may help researchers develop 
further interventions to increase influenza vaccination.
10.3. Adverse Events
Adverse events will not be actively collected because no pharmaceutical product or medical
treatment will be provided or evaluated in this study . Spontaneously reported adverse events 
received by Evidation Health will be recorded per Evidation Health's Standard Operating
Procedures.
Any pharmacovigilance data pertaining to a Sanofi product potentially collected will be notified
by Evidation Health to Sanofi Pasteur Pharmacovigilance, who is working with Evidation on this
research project, through email (
CL-CPV -Receipt@sanofi.com
),
within 1 (one) working day for 
serious adverse events.
A â€œserious adverse event (SAE)â€ is defined as any untoward medical occurrence that at any
dose: 
â—
Results in death, 
â—
Is life threatening, (Note: the term â€œlife-threateningâ€ refers to an event/reaction in which
the patient was at risk of death at the time of the event/reaction; it does not refer to an
event/ reaction which hypothetically might have caused death if it were more severe), 
â—
Requires inpatient hospitalization or results in prolongation of existing hospitalization, 
â—
Results in persistent or significant disability/incapacity , 
â—
Is a congenital anomaly/birth defect, or 
â—
Is a medically important event or reaction. Medical and scientific judgment should be
exercised in deciding whether other situations should be considered serious, such as
important medical events that might not be immediately life-threatening or result in death
or hospitalization, but might jeopardize the patient or might require intervention to
prevent one of the other outcomes listed in the definition above.
Version 1
20
of
22
Appendix
Please see attached appendix for examples of the intervention messages.
References
Centers for Disease Control and Prevention (CDC). (2018). â€œSeasonal Influenza Vaccine
Effectiveness, 2016-2017.â€ Retrieved from
https://www .cdc.gov/flu/vaccines-work/2016-2017.html
Centers for Disease Control and Prevention (CDC) (2019). "Flu & Heart Disease and Stroke."
from
https://www .cdc.gov/flu/highrisk/heartdisease.htm
.
Centers for Disease Control and Prevention (CDC) (2019). FluV axView Interactive, National
Center for Immunization and Respiratory Diseases (NCIRD), from
https://www .cdc.gov/flu/fluvaxview/interactive-help.htm
Dale, L. P ., et al. (2019). "Smartphone app uses loyalty point incentives and push notifications to
encourage influenza vaccine uptake."
Vaccine
37
(32):
4594-4600.
Dos Santos, G., Tahrat, H., & Bekkat-Berkani, R. (2018). Immunogenicity , safety , and
effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: A systematic
review . Human vaccines & immunotherapeutics, 14(8), 1853-1866.
doi:10.1080/21645515.2018.1446719
Doyle, JD, Chung, JR, Kim, SS, et al (2019). Interim Estimates of 2018â€“19 Seasonal Influenza
Vaccine Ef fectiveness â€” United States, February 2019. MMWR Morb Mortal Wkly Rep 2019;
68:135â€“139. doi: 10.15585/mmwr .mm6806a2
Frank L, Basch E, Selby JV , For the Patient-Centered Outcomes Research Institute. (2014). The 
PCORI Perspective on Patient-Centered Outcomes Research.
JAMA
, 312(15):1513â€“1514. Doi: 
10.1001/jama.2014.1 1100
Healthy People 2020. (2019). Retrieved from https://www .healthypeople.gov/. from Healthy
People 2020, United States Department of Health and Human Services, Of fice of Disease
Prevention and Health Promotion,
https://www .healthypeople.gov/
Version 1
21
of
22
Hurley LP , Beaty B, Lockhart S, Gurfinkel D, Breslin K, Dickinson M, Whittington MD, Roth
H, Kempe A. RCT  of Centralized Vaccine Reminder/Recall for Adults. Am J Prev Med. 2018
Aug;55(2):231-239.
Jackson, M. L., Chung, J. R., Jackson, L. A., Phillips, C. H., Benoit, J., Monto, A. S., . . .
Flannery , B. (2017). Influenza Vaccine Ef fectiveness in the United States during the 2015â€“2016
Season. New England Journal of Medicine, 377(6), 534-543. doi:10.1056/NEJMoa1700153
Lee, W.-N., et al. (2020). "Lar ge-scale influenza vaccination promotion on a mobile app
platform: A randomized controlled trial."
Vaccine
38
(18): 3508-3514.
Molinari, N.-A. M., Ortega-Sanchez, I. R., Messonnier , M. L., Thompson, W. W., Wortley , P. M.,
Weintraub, E., & Bridges, C. B. (2007). The annual impact of seasonal influenza in the US:
Measuring disease burden and costs. Vaccine, 25(27), 5086-5096. doi:
10.1016/j.vaccine.2007.03.046
Nehme EK, Delphia M, Cha EM, Thomas M, Lakey D. Promoting Influenza Vaccination Among
an ACA  Health Plan Subscriber Population: A Randomized Trial. Am J Health Promot. 2019
Jul;33(6):916-920.
Rolfes, M. A., Flannery , B., Chung, J. R., Oâ€™Halloran, A., Gar g, S., Belongia, E. A., . . .
Prevention. (2019). Ef fects of Influenza Vaccination in the United States During the 2017â€“2018
Influenza Season. Clinical Infectious Diseases, 69(1 1), 1845-1853. doi:10.1093/cid/ciz075
Samson, S., Lee, J., Tai, C.,â€¦ & Foschini, L. (2020, September). Digital intervention is ef fective 
at increasing influenza vaccination in people living with diabetes. Poster presented at the
European Association for the Science of Diabetes in Vienna, Austria â€“ Conference to occur 
digitally 22-25 September , 2020 due to COVID-19.
Samson, S. I., et al. (2019). "Quantifying the Impact of Influenza Among Persons With Type 2
Diabetes Mellitus: A New Approach to Determine Medical and Physical Activity Impact."
Journal of Diabetes Science and Technology
: 1932296819883340.
Zhong B. How to calculate sample size in randomized controlled trial?.
J Thorac Dis
.
2009;1(1):51â€“54.
Version 1
22
of
22